News
![](https://kamaripharma.com/wp-content/uploads/2024/05/researchers-are-working-on-product-development-mo-2023-11-27-05-23-43-utc-scaled.jpg)
KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratoderma
READ MORE >
![](https://kamaripharma.com/wp-content/uploads/2024/05/young-woman-analyzing-data-charts-for-marketing-fi-2023-11-27-05-17-32-utc-1-scaled.jpg)
Novel TRPV3 inhibitors developed for the treatment of palmoplantar keratodermas, demonstrate safety and efficacy in preclinical models
READ MORE >
![](https://kamaripharma.com/wp-content/uploads/2024/05/headway-F2KRf_QfCqw-unsplash-scaled.jpg)
Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology
READ MORE >
![](https://kamaripharma.com/wp-content/uploads/2024/05/hannah-busing-Zyx1bK9mqmA-unsplash-scaled.jpg)
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
READ MORE >
![](https://kamaripharma.com/wp-content/uploads/2022/11/kamari_news3.jpg)
Lichen Simplex Chronicus Itch: An Update
READ MORE >
![](https://kamaripharma.com/wp-content/uploads/2021/10/papeline1-mob_440X640.jpg)
TRPV3 antagonist treatment reduces pro-inflammatory pathways in Olmsted syndrome keratinocytes
READ MORE >
![](https://kamaripharma.com/wp-content/uploads/2022/10/article1.jpg)
Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund
READ MORE >